3.4.21.109: matriptase
This is an abbreviated version!
For detailed information about matriptase, go to the full flat file.
Word Map on EC 3.4.21.109
-
3.4.21.109
-
hepatocyte
-
hepcidin
-
hai-1
-
anemia
-
metastasis
-
prostate
-
hepsin
-
zymogen
-
transferrin
-
prostasin
-
overload
-
trypsin-like
-
irida
-
plasminogen
-
hemojuvelin
-
iron-refractory
-
kunitz-type
-
inhibitor-1
-
kunitz
-
ttsps
-
hemochromatosis
-
erythropoiesis
-
microcytic
-
membrane-anchored
-
urokinase-type
-
ferroportin
-
iron-deficiency
-
pro-hgf
-
pericellular
-
upa
-
autoactivation
-
two-chain
-
hypochromic
-
medicine
-
protease-activated
-
tmprss4
-
spint2
-
corpuscular
-
erythroferrone
-
profilaggrin
-
camostat
-
corin
-
epithelial-derived
-
par-2
-
hypotrichosis
-
drug development
-
diagnostics
- 3.4.21.109
- hepatocyte
- hepcidin
- hai-1
- anemia
- metastasis
- prostate
- hepsin
- zymogen
- transferrin
- prostasin
- overload
-
trypsin-like
-
irida
- plasminogen
- hemojuvelin
-
iron-refractory
-
kunitz-type
- inhibitor-1
-
kunitz
-
ttsps
- hemochromatosis
-
erythropoiesis
-
microcytic
-
membrane-anchored
-
urokinase-type
-
ferroportin
-
iron-deficiency
- pro-hgf
-
pericellular
- upa
-
autoactivation
-
two-chain
-
hypochromic
- medicine
-
protease-activated
-
tmprss4
-
spint2
-
corpuscular
-
erythroferrone
- profilaggrin
- camostat
- corin
-
epithelial-derived
- par-2
- hypotrichosis
- drug development
- diagnostics
Reaction
cleaves various synthetic substrates with Arg or Lys at the P1 position and prefers small side-chain amino acids, such as Ala and Gly, at the P2 position =
Synonyms
Epi/MTP, epithin, epithin/matriptase, influenza virus-activating protease, matriptase, matriptase-1, matriptase-2, matriptase-3, matriptase1, matriptase1a, membrane-type serine protease 1, membrane-type serine protease 1/matripase, membrane-type serine protease-1, membrane-type serine protease1, membrane-type serine proteinase matripase, membrane-type serine proteinase matriptase, More, MT-2, MT-SP-1, MT-SP1, MT-SP1/matripase, MT2, notopleural, prostamin, PRSS14, r-matripase, serine protease matriptase-2, serine protease SNC19/matripase, SNC19, ST-14, ST14, suppression of tumorigenecity 14, suppressor of tumorigenicity 14, suppressor of tumorigenicity 14 protein, suppressor of tumorigenicity-14, TADG-15, TADG15, TMPRSS6, transmembrane serine protease 6, tumor-associated differentially expressed gene-15, tumor-associated type II transmembrane serine protease, type 2 transmembrane serine protease, type II transmembrane protease, type II transmembrane serine protease
ECTree
3.4.21.109 matriptaseAdvanced search results
results (
results (Activating Compound
Activating Compound on EC 3.4.21.109 - matriptase
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
top
ACTIVATING COMPOUND 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
IMAGE
4,4'-diisothiocyanatostilbene-2,2' disulfonic acid
-
as an early response to acidosis, matriptase activation can also be induced by perturbation of intracellular pH homeostasis using substances inhibiting Na+/H+ exchangers or other acid-base ion channels
5-(N-ethyl-N-isopropyl)-amiloride
-
as an early response to acidosis, matriptase activation can also be induced by perturbation of intracellular pH homeostasis using substances inhibiting Na+/H+ exchangers or other acid-base ion channels
5-(N-methyl-N-isobutyl)-amiloride
-
as an early response to acidosis, matriptase activation can also be induced by perturbation of intracellular pH homeostasis using substances inhibiting Na+/H+ exchangers or other acid-base ion channels
C2 ceramide 1-phosphate
-
weaker activator than sphingosine 1-phosphate, activation at 0.000237 mM
C8 ceramide 1-phosphate
-
weaker activator than sphingosine 1-phosphate, activation at 0.001 mM
Epidermal growth factor
-
stimulates the release of matripase/hepatocyte growth factor activator inhibitor-1 complexes
H+
-
exposure of epithelial and carcinoma cells to a mildly acidic extracellular milieu pH 6.0 results in robust matriptase activation
hepatocyte growth factor activator inhibitor
HAI-1, zymogen activator of matriptase
-
Ibuprofen
-
matriptase zymogen is down-regulated in the UROtsa cells by ibuprofen
N-acetylglucosaminyltransferase V
-
the transient overexpression of N-acetylglucosaminyltransferase V, MGAT5, significantly enhances the activity of matriptase
-
prostasin
-
prostasin stimulates the conversion of the cell-associated 70-kDa matriptase zymogen to the two-chain active form. Prostasin induces matriptase zymogen activation in intestinal epithelial cells to regulate closure of the paracellular pathway. But active recombinant matriptase, however, does not require the expression of endogenous prostasin for barrier-forming activity
-
serum
from human, horse, mouse, rat, rabbit, duck, chicken, goat, calf, turtle and foetal bovine serum, leads to increase of the level of the active two-chain form
-
sphingosine 1-phosphate
-
activation at 0.00001 mg/ml, activation is dependent on Ca2+
sphingosine 1-phosphate
-
mediates translocation of the enzyme to cell-cell junctions, sphingosine 1-phosphate-induced matripase activation is enhancend by reduced hepatocyte growth factor activator inhibitor-1 expression
additional information
-
activation of the matriptase zymogen requires sequential N-terminal cleavage, activation site autocleavage, and transient association with HAI-1, different activation mechanisms, matriptase translocates to the cell surface and is activated within min after exposure of breast cancer cells to sphingosine-1-phosphate, a serum-derived lipid that signals through specific G-protein-coupled receptor, this activation process was shown to require actin cytoskeleton remodeling, overview
-
additional information
-
prolonged stabilization of matriptase by GnT-V-mediated glycosylation in vivo, thus extending its half-life and permitting it to play role in the early phases of papillary carcinoma, but not in its later phase progression, overview
-
additional information
-
the enzyme is induced by lysophospholipids, androgens, and the polyanionic suramin, the agents induce different signaling pathways and cellular events in a cell type-specific manner leading to matriptase activation, which requires an intact lipid bilayer microenvironment, enzyme activation within the range of pH 5.2-7.2, overview, inhibition of matriptase activation in vitro and in vivo, overview
-
additional information
-
zymogen activation is stimulated by suramin, lysophosphatidic acid, and sphingosine 1-phosphate, overview
-
additional information
controlled by a serpin complex, consisting of antithrombin III, alpha1-antitrypsin and alpha2-antiplasmin
-
additional information
-
controlled by a serpin complex, consisting of antithrombin III, alpha1-antitrypsin and alpha2-antiplasmin
-
additional information
-
under normal conditions the activity of matriptase is tightly regulated by the endogenous hepatocyte growth factor activator inhibitors HAI-1 and, or HAI-2
-
additional information
-
it is shown that hepatocyte growth factor activator inhibitor type-1 is not required for activation of matriptase in stably transfected Madin-Darby canine kidney cells
-
